Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?
The optimal conditioning regimen for older patients with AML remains unclear. Here we compared outcomes of AML patients above 60 years receiving AHCT at our institution. All 404 consecutively treated patients received one of the following conditioning regimens: 1) fludarabine + melphalan 100mg/m2 (FM100), 2) fludarabine + melphalan 140mg/m2 (FM140), 3) fludarabine + IV busulfan AUC{greater than or equal to}5,000/day x 4 days (Bu{greater than or equal to}20000), and 4) fludarabine + IV busulfan AUC 4,000/day x 4 days (Bu16000) were included. A propensity score analysis (PSA) was used to compare outcomes between these 4 groups. Among the 4 conditioning regimens, FM100 group had a significantly better long-term survival with 5-year progression-free survival (PFS) of 49% vs. 30%, 34% and 23%, respectively. The benefit of FM100 regimen resulted primarily from a lower non-relapse mortality associated with this regimen, effect more pronounced in patients with lower performance status. The PSA confirmed that FM100 was associated with better post-transplant survival, while no significantly differences were seen between other regimen groups. In conclusion, older patients with AML benefit from a reduced-intensity conditioning regimen with lower melphalan doses (FM100), which was associated with better survival despite the fact that was primarily used in patients who could not receive more intense conditioning regimen.